The “Polonium In Vivo” Study: Polonium-210 in Bronchial Lavages of Patients with Suspected Lung Cancer
Authors:
- Vincenzo ZagàVZVincenzo Zagà
- Maria Sofia CattaruzzaMCMaria Sofia Cattaruzza
- Paola MartucciPMPaola Martucci
- Roberta PacificiRoberta Pacifici
- Rocco TrisoliniRocco Trisolini
- Paolo BartolomeiPBPaolo Bartolomei
- Raffaela GiacobbeRGRaffaela Giacobbe
- Marco PatelliMPMarco Patelli
- Daniela PaioliDPDaniela Paioli
- Massimo EspositoMEMassimo Esposito
- Valeria FabbriVFValeria Fabbri
- Silvano GallusSilvano Gallus
Open Access
- 23 December 2020
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 9 (1) , 4
Abstract
Few studies have reported on polonium-210, a decay breakdown product of radon-222 and lead-210, in human lungs and there has been no study in patients with suspected lung cancer. The main aim of this “Polonium in vivo” study was to evaluate polonium-210 radioactivity in bronchopulmonary systems of smoker, ex-smoker and never smoker patients with suspected lung cancer. Alpha-spectrometric analyses were performed on bronchial lavage (BL) fluids from two Italian hospitals in 2013–2016. Socio-demographic, smoking, occupational and spirometric characteristics, lung cancer confirmation and histologic type and radon-222 concentration in patients’ homes were collected. Seventy BL samples from never (n = 13), former (n = 35) and current smokers (n = 22) were analyzed; polonium-210 was detected in all samples from current and former smokers and in 54% of samples from never smokers (p < 0.001; median values: 1.20, 1.43 and 0.40 mBq, respectively). Polonium-210 levels were significantly higher in COPD versus no COPD patients (median value: 3.60 vs. 0.97 mBq; p = 0.007); former and current smokers, without and with COPD, had significantly increased polonium-210 levels (p = 0.012); 96% of confirmed versus 69% of non-confirmed lung cancer patients recorded detectable polonium-210 levels (p = 0.018). A polonium-210 detectable activity was measured in BL samples from all current and former smokers. Polonium-210 in the lungs could be the result of lead-210 entrapment, which, with its half-life of 22 years, could provide a continuous emission of alpha radioactivity, even many years after quitting, thus proposing a possible explanation for the onset of lung cancer, particularly in former smokers.Keywords
This publication has 21 references indexed in Scilit:
- Polonium and Lung CancerJournal of Oncology, 2011
- COPD prevalence is increased in lung cancer, independent of age, sex and smoking historyEuropean Respiratory Journal, 2009
- Waking a Sleeping Giant: The Tobacco Industry’s Response to the Polonium-210 IssueAmerican Journal of Public Health, 2008
- Prevalence of COPD in Women Compared to Men Around the Time of Diagnosis of Primary Lung CancerChest, 2006
- COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinomaThorax, 2004
- Clearance of polonium-210-enriched cigarette smoke from the rat trachea and lungToxicology and Applied Pharmacology, 1985
- Histochemical, light and electron microscopic study of polonium-210 induced peripheral tumors in hamster lungs: Evidence implicating the Clara cell as the cell of origin1977
- Deposition and clearance of 2 μ particles in the tracheobronchial tree of normal subjects—smokers and nonsmokersJournal of Clinical Investigation, 1971
- Lung Cancer Following Polonium-210 Inhalation in RatsRadiation Research, 1967
- Polonium-210: A Volatile Radioelement in CigarettesScience, 1964